1. Home >
  2. M&A >
  3. Venture >
  4. United States >
  5. New York >
  6. Aisling Capital Invests In Tourmaline Bio

Investment Summary

Aisling Capital Invests In Tourmaline Bio

On October 6, 2020, private equity firm Aisling Capital invested in life science company Tourmaline Bio

Investment Highlights
  • This is Aisling Capital’s 41st transaction in the Life Science sector.
  • This is Aisling Capital’s 50th transaction in the United States.
  • This is Aisling Capital’s 7th transaction in New York.
Investment Fate
  • Tourmaline Bio went public in 2021.

Investment Summary
Date 2020-10-06
Target Tourmaline Bio
Sector Life Science
Investor(s) Aisling Capital
Deal Type Venture

Target

Tourmaline Bio

New York, New York, United States
Tourmaline Bio is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Tourmaline Bio was founded in 2021 and is based in New York, New York.

Search 214,877 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Aisling Capital

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 1.8B USD
Size Large
Type Sector Focused
DESCRIPTION

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.

DEAL STATS #
Overall 53 of 56
Sector: Life Science M&A 41 of 42
Type: Venture M&A Deals 28 of 29
State: New York M&A 7 of 7
Country: United States M&A 50 of 52
Year: 2020 M&A 4 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-10-05 Eidos Therapeutics

San Francisco, California, United States

Eidos Therapeutics is a biopharmaceutical company developing therapies to treat transthyretin amyloidosis (ATTR), primarily in the heart. Eidos Therapeutics was founded in 2013 and is headquartered in San Francisco, California.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-11-24 Monte Rosa Therapeutics

Boston, Massachusetts, United States

Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection, and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa Therapeutics was founded in 2018 and is based in Boston, Massachusetts.

Buy -
Mergr

Solution for

Product

Company

Legal